NCT02593786View on ClinicalTrials.gov

A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 7, 2016

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions
Solid Tumors
Interventions
DRUG

Nivolumab

Trial Locations (2)

310016

Local Institution, Hangzhou

510060

Local Institution - 0001, Guangzhou

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY